HR Execs on the Move

Revolution Medicines

www.revmed.com

 
REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. We pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.revmed.com
  • 700 Saginaw Drive
    Redwood City, CA USA 94063
  • Phone: 650.481.6801

Executives

Name Title Contact Details
Daniel Simon
Chief Business Officer Profile
Jack Anders
Chief Financial Officer Profile
Steve Ballmer
Director, Strategic Sourcing and Supplier Profile
Zack Rokos
Director, Total Rewards and HRBP Profile

Similar Companies

Bioscience

Bioscience, Inc. is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Inocucor

The Phyto-Microbiome Company Biological Optimizers for Soil, Seed and Plant Vigor Inocucor is an agri-tech company that develops powerful natural biological products for agriculture targeting the phyto-microbiome—the seeds, plants, root systems and the soil surrounding them. Inocucor`s first-generation product, Garden Solution®, soon to be re-branded as Synergro, employs live microbes to actively improve the health of the entire phyto-microbiome. Its second product, Synergro Free and future generations of Inocucor products are powerful biological formulations for bio-stimulation, bio-fertility and bio-control targeting mainstream production agriculture.

Enzyme by Design

A protein engineering startup passionate about developing safer cancer therapeutics

maryville academy

maryville academy is a Des Plaines, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Virobay

Virobay is focused on the development and commercialization of novel drugs through the utilization of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases, for a variety of conditions, including neuropathic pain, autoimmune diseases and fibrosis.  The foundation of Virobay's proprietary cathepsin platform and the Virobay management team were spun-out from Celera Genomics, which was then a leader in cathepsin research. Virobay's clinical pipeline currently includes product candidates in neuropathic pain, dermatology, autoimmune disease and fibrosis.